Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 16/20 | 0.53 |
| ▸ | HTR1B | P28222 | 11/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31727562 | 0.96 | HTR1D (0.53) | HTR1DHTR1BKIF11 | |
| SCHEMBL8316304 | 0.77 | HTR1D (0.56) | HTR1DHTR1BDRD2DRD4DRD3 | |
| SCHEMBL7617146 | 0.76 | PNMT (0.49) | HTR1DHTR1B | |
| SCHEMBL17498081 | 0.74 | BRD4 (0.46) | HTR1DHTR1B | |
| SCHEMBL20582819 | 0.74 | HTR1D (0.50) | HTR1DHTR1B | |
| SCHEMBL5917114 | 0.72 | HTR1D (0.62) | HTR1DHTR1B | |
| SCHEMBL12918864 | 0.72 | HTR1D (0.55) | HTR1DHTR1B | |
| SCHEMBL7392855 | 0.72 | HTR1D (0.51) | HTR1DHTR1BDRD2DRD3 | |
| SCHEMBL180561 | 0.72 | HTR1D (0.39) | HTR1DHTR1BAHR | |
| SCHEMBL917625 | 0.71 | PARP1 (0.43) | KIF11BCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-0690843-B1 | Formyl- or cyano- substituted indole derivatives having dopaminergic activity | UPJOHN CO (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0510068-B1 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | UPJOHN CO (US) | 1999-04-14 | — | — | EP | disclosed |
| US-5650427-A | ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1997-07-22 | — | — | US | disclosed |
| US-5639778-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0690843-A1 | INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5461061-A | Antidepressants | WIKSTROM HAKAN V (NL) | 1995-10-24 | — | — | US | disclosed |
| WO-1994021608-A1 | INDOLETETRALINS HAVING DOPAMINERGIC ACTIVITY | THE UPJOHN COMPANY (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0510068-A1 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | PHARMACIA & UPJOHN COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| EP-0510068-A1 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | PHARMACIA & UPJOHN COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1991011435-A3 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(E)INDOLE HETEROCYCLICS | UPJOHN CO (US) | 1991-09-05 | — | — | WO | disclosed |
| WO-1991011435-A2 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | THE UPJOHN COMPANY (US) | 1991-08-08 | — | — | WO | disclosed |
| WO-1991011435-A2 | NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS | THE UPJOHN COMPANY (US) | 1991-08-08 | — | — | WO | disclosed |
| US-4510157-A | 6,7,8,9-Tetrahydro-1H-benz(g)indol-8-amine derivatives | AYERST, MCKENNA & HARRISON, INC. (CA) | 1985-04-09 | — | — | US | disclosed |
| EP-0055043-B1 | 6,7,8,9-TETRAHYDRO-3H-BENZ(E)INDOLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND INTERMEDIATES USED THEREIN, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE INDOLAMINE DERIVATIVES | AYERST, MCKENNA AND HARRISON INC. (CA) | 1985-01-23 | — | — | EP | disclosed |
| US-4454150-A | 6,7,8,9-Tetrahydro-3H-benz(e)indol-7-amines and a method of dopamine receptor stimulation therewith | AYERST, MCKENNA & HARRISON INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4370341-A | 6,7,8,9-Tetrahydro-3H-benz[E]indol-8-amine derivatives | AYERST, MCKENNA & HARRISON, LTD. (CA) | 1983-01-25 | — | — | US | disclosed |
| EP-0055043-A2 | 6,7,8,9-Tetrahydro-3H-benz(e)indolamine derivatives, processes for their preparation and intermediates used therein, and pharmaceutical compositions containing the indolamine derivatives | AYERST, MCKENNA AND HARRISON INC. (CA) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TPH2, TPH1, AANAT | HTR1D 59/4885HTR1B 22/4885KIF11 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.